A diversified pipeline with a singular focus on patient need

We are building a diverse portfolio of product candidates designed to address the unmet medical needs of patients with cancer or autoimmune diseases and to maximize our opportunities for clinical and commercial success.
PROGRAM INDICATION   PRECLINICAL PHASE I PHASE II PIVOTAL/PHASE III
Brentuximab Vedotin
(SGN-35)		Relapsed/refractory Hodgkin lymphoma (HL) 
Post-transplant HL relapse prevention (AETHERA trial) 
Systemic anaplastic large cell lymphoma (ALCL) 
 
Retreatment of Hodgkin lymphoma, systemic ALCL 
 
Front-line Hodgkin lymphoma (+ chemotherapy) 
  
Lintuzumab
(SGN-33) 		Acute myeloid leukemia
(AML) (low-dose cytarabine
+/- lintuzumab)		 
 
Myelodysplastic syndromes (+ Vidaza) 
 
Dacetuzumab
(SGN-40)		Diffuse large B-cell
lymphoma (+ Rituxan/Gemzar)		 
  
Indolent non-Hodgkin
lymphoma (+ Rituxan)		 
  
Multiple myeloma
(+ Revlimid)		 
  
Multiple myeloma (+ Velcade) 
  
SGN-70Autoimmune diseases 
  
SGN-75Renal cell carcinoma, non-Hodgkin lymphoma 
  
ASG-5MEPancreatic cancer 
  
Prostate cancer 
   
SGN-19AHematologic malignancies 
   
 Antibody-drug conjugate  
Engineered monoclonal antibody
Privacy Policy  |  Legal Notice